Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NEAL D SHORE

Allopathic & Osteopathic Physicians Urology

NPI
1265423453
CMS profile
11507
Location
MYRTLE BEACH, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$462,516.57

363 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 8; records 151–200 of 363 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NEAL D SHORE

NPI 1265423453 · CMS profile ID 11507

Allopathic & Osteopathic Physicians / Urology

MYRTLE BEACH, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 8; records 151–200 of 363 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265423453?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NEAL D SHORE, NPI 1265423453, CMS profile ID 11507. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 8; records 151–200 of 363 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265423453?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). NEAL D SHORE, NPI 1265423453, CMS profile ID 11507. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 8; records 151–200 of 363 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265423453?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
NEAL D SHORE, NPI 1265423453, CMS profile ID 11507, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 8; records 151–200 of 363 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1265423453?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

363 matching records · $462,516.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 363 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 363.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer HealthCare Pharmaceuticals Inc. $208.9708/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628411363 CMS
Bayer HealthCare Pharmaceuticals Inc. $6,160.0008/08/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628436137 CMS
Bayer HealthCare Pharmaceuticals Inc. $486.3208/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628444435 CMS
Bayer HealthCare Pharmaceuticals Inc. $14.2408/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628445127 CMS
Bayer HealthCare Pharmaceuticals Inc. $4,340.0008/08/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628449349 CMS
Integra GPO, LLC $5,225.0007/31/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 639791449 CMS
Photocure Inc $21.9507/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686772191 CMS
Janssen Biotech, Inc. $500.0007/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658714441 CMS
GENZYME CORPORATION $125.0007/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694165503 CMS
GENZYME CORPORATION $6,615.0007/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694165513 CMS
GENZYME CORPORATION $497.6207/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694165515 CMS
GENZYME CORPORATION $638.1507/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694165517 CMS
GENZYME CORPORATION $129.4607/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694165519 CMS
AstraZeneca UK Limited $2,000.0007/17/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685802845 CMS
EMD Serono, Inc. $13.1407/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702999327 CMS
PFIZER INC. $11.4907/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672476561 CMS
ROCHESTER MEDICAL CORPORATION $22.5407/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699867029 CMS
Clovis Oncology, Inc. $23.6807/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688689499 CMS
Janssen Biotech, Inc. $1,000.0007/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658714437 CMS
Astellas Pharma Global Development $1,250.0007/11/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 641930265 CMS
AstraZeneca UK Limited $1,500.0007/09/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685178435 CMS
GENZYME CORPORATION $11.7207/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694260559 CMS
GENZYME CORPORATION $351.1107/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694260561 CMS
GENZYME CORPORATION $7,788.0007/08/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694260563 CMS
SANOFI-AVENTIS U.S. LLC $4.2207/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694138345 CMS
Bayer HealthCare Pharmaceuticals Inc. $12.0006/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628452415 CMS
Integra GPO, LLC $1,375.0006/28/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 639791439 CMS
Coloplast Corp $106.1006/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696982683 CMS
Genentech USA, Inc. $12.0706/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681304043 CMS
PFIZER INC. $1,500.0006/24/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672433957 CMS
Bayer HealthCare Pharmaceuticals Inc. $1,960.0006/21/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628442581 CMS
Janssen Global Services, LLC $2,480.0006/20/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708407121 CMS
Coloplast Corp $11.8406/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696982681 CMS
AbbVie, Inc. $13.6906/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648069545 CMS
Bayer HealthCare Pharmaceuticals Inc. $64.1406/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628481927 CMS
Bayer HealthCare Pharmaceuticals Inc. $170.9006/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628491849 CMS
Ferring International Center SA $43.6206/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655172413 CMS
Ferring International Center SA $37.0006/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655172415 CMS
Ferring International Center SA $20.0006/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655172417 CMS
Ferring International Center SA $14.0006/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655172419 CMS
Ferring International Center SA $14.0006/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655172421 CMS
Ferring International Center SA $10.0006/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655172423 CMS
Janssen Research & Development, LLC $1,100.0006/13/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657419021 CMS
Merck Sharp & Dohme Corporation $150.0006/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695643139 CMS
Merck Sharp & Dohme Corporation $5,500.0006/13/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695643142 CMS
Ferring International Center SA $260.3306/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655172405 CMS
Ferring International Center SA $58.7406/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655172407 CMS
Ferring International Center SA $28.0006/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655172409 CMS
Ferring International Center SA $73.6706/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655172411 CMS
Ferring International Center SA $44.8206/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655172401 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $462,516.57 363
PY2020 $418,809.44 248
PY2021 $302,089.41 234
PY2022 $375,612.10 228
PY2023 $719,592.14 266
PY2024 $449,311.14 268
PY2025 $448,070.23 240

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $65,684.95 57
PY2025 Principal investigator $8,002,667.16 491
PY2024 Recipient $57,211.77 44
PY2024 Principal investigator $8,224,282.07 738
PY2023 Recipient $60,749.73 82
PY2023 Principal investigator $7,187,000.63 539
PY2022 Recipient $36,625.82 60
PY2022 Principal investigator $7,706,559.16 458
PY2021 Recipient $24,657.08 55
PY2021 Principal investigator $12,525,672.72 427
PY2020 Recipient $21,543.29 45
PY2020 Principal investigator $9,666,548.35 645
PY2019 Recipient $16,681.00 65
PY2019 Principal investigator $6,834,236.00 390

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

548 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,236.75 12/31/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401695
Principal investigator 1 Merck Sharp & Dohme LLC $10,129.43 12/31/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett No dispute reported 06/30/2026 1232925155
Principal investigator 1 Merck Sharp & Dohme LLC $22,662.47 12/31/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
Phase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-365 No dispute reported 06/30/2026 1232925771
Principal investigator 1 Merck Sharp & Dohme LLC $37,491.28 12/31/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926743
Principal investigator 1 Merck Sharp & Dohme LLC $12,091.56 12/31/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 1232926917
Principal investigator 1 Merck Sharp & Dohme LLC $22,150.54 12/31/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle- No dispute reported 06/30/2026 1232927475
Principal investigator 1 Merck Sharp & Dohme LLC $13,942.79 12/31/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer No dispute reported 06/30/2026 1232927751
Principal investigator 1 Merck Sharp & Dohme LLC $12,322.38 12/31/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 No dispute reported 06/30/2026 1232927983
Principal investigator 1 Novartis Pharmaceuticals Corporation $194.33 12/31/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment No dispute reported 06/30/2026 1190313875
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,560.11 12/31/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190313881
Principal investigator 1 PFIZER INC. $3,980.00 12/31/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228749938
Principal investigator 1 PFIZER INC. $42,129.00 12/31/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
AN INTERVENTIONAL PHASE 1B2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA No dispute reported 06/30/2026 1228750366
Principal investigator 1 PFIZER INC. $9,352.00 12/30/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228743871
Principal investigator 1 Janssen Research & Development, LLC $48,707.00 12/29/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175355106
Principal investigator 1 Janssen Research & Development, LLC $5,169.00 12/29/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175355331
Principal investigator 1 Merck Sharp & Dohme LLC $261,443.85 12/29/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926567
Principal investigator 1 Janssen Research & Development, LLC $12,230.00 12/25/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1175354949
Principal investigator 1 PFIZER INC. $9,811.80 12/25/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF08052667 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH BLADDER CANCER No dispute reported 06/30/2026 1228744909
Principal investigator 1 Exelixis Inc. $5,966.35 12/23/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222380318
Principal investigator 1 Merck Sharp & Dohme LLC $57,779.50 12/23/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle- No dispute reported 06/30/2026 1232927473
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $325.83 12/19/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411650
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $325.83 12/19/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411704
Principal investigator 1 Janssen Research & Development, LLC $2,348.00 12/19/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer No dispute reported 06/30/2026 1175354611
Principal investigator 1 Janssen Research & Development, LLC $3,666.50 12/18/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175354957
Principal investigator 1 PFIZER INC. $46,207.89 12/18/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726392
Recipient PFIZER INC. $1,400.00 12/18/2025 Covered Recipient Physician MEVROMETOSTAT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727363
Principal investigator 1 PFIZER INC. $46,207.89 12/16/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 No dispute reported 06/30/2026 1228716589
Principal investigator 1 PFIZER INC. $1,578.20 12/16/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228745907
Principal investigator 1 Janssen Research & Development, LLC $10,800.00 12/15/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175354915
Principal investigator 1 Janssen Research & Development, LLC $1,556.00 12/15/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175355365
Principal investigator 1 PFIZER INC. $12,852.28 12/13/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228731471
Principal investigator 1 PFIZER INC. $5,420.10 12/13/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228745138
Principal investigator 1 MEDIVATION LLC. $17,581.20 12/11/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228739104
Principal investigator 1 PFIZER INC. $3,500.00 12/06/2025 Non-covered Recipient Entity
START San Antonio LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 No dispute reported 06/30/2026 1228730951
Principal investigator 1 PFIZER INC. $6,300.00 12/04/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228723164
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 12/03/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401685
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 12/03/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401687
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 12/03/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401703
Principal investigator 1 Dendreon Pharmaceuticals LLC $7,769.00 12/03/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
PROVONE STUDY No dispute reported 06/30/2026 1247892670
Principal investigator 1 Exelixis Inc. $4,621.45 12/01/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222380316
Principal investigator 1 Janssen Research & Development, LLC $11,762.00 12/01/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175354669
Principal investigator 1 Janssen Research & Development, LLC $32,920.00 12/01/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175354750
Principal investigator 1 Janssen Research & Development, LLC $600.00 12/01/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175354861
Principal investigator 1 Janssen Research & Development, LLC $36,322.00 12/01/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) No dispute reported 06/30/2026 1175355012
Principal investigator 1 Janssen Research & Development, LLC $4,256.00 12/01/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175355339
Principal investigator 1 Laborie Medical Technologies Corp. $1,101.00 12/01/2025 Non-covered Recipient Entity
CURC Carolina Urologic Research Ctr LLC
PINNACLE No dispute reported 06/30/2026 1250724520
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,040.48 12/01/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer No dispute reported 06/30/2026 1190309294
Principal investigator 1 PFIZER INC. $46,207.89 12/01/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228718580
Principal investigator 1 Janssen Research & Development, LLC $3,255.00 11/28/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175354597
Principal investigator 1 Janssen Research & Development, LLC $2,917.00 11/28/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175354638
Principal investigator 1 Janssen Research & Development, LLC $5,419.00 11/28/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1175355182
Principal investigator 1 PFIZER INC. $46,207.89 11/27/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228717245
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,733.68 11/26/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409594
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,339.92 11/26/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409612
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,733.68 11/26/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409716
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $252.00 11/26/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409894
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $21,164.00 11/26/2025 Non-covered Recipient Entity
Carolina Urologic Research Center, Llc
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge No dispute reported 06/30/2026 1235998390
Principal investigator 1 PFIZER INC. $12,515.80 11/26/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228716511
Principal investigator 1 PFIZER INC. $46,900.00 11/26/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF08052667 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH BLADDER CANCER No dispute reported 06/30/2026 1228739066
Principal investigator 1 PFIZER INC. $9,163.70 11/25/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228737474
Principal investigator 1 PFIZER INC. $1,785.22 11/25/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228739141
Principal investigator 1 PFIZER INC. $1,200.00 11/24/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH
A STUDY OF INTRAVESICAL ENFORTUMAB VEDOTIN FOR TREATMENT OF PATIENTS WITH NONMUSCLE INVASIVE BLADDER CANCER NMIBC No dispute reported 06/30/2026 1228730200
Principal investigator 1 Janssen Research & Development, LLC $7,463.00 11/21/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175355064
Principal investigator 1 Novartis Pharmaceuticals Corporation $471.75 11/19/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177 No dispute reported 06/30/2026 1190313877
Principal investigator 1 AstraZeneca UK Limited $34,250.00 11/14/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
a randomized,double blind,placebo controlled,phase third study of adjuvant saruparib AZD5305 in patients with bracam localized high risk prostate cancer receiving radiotherapy with aqndrogen deprivation therapy evo par prostate No dispute reported 06/30/2026 1185542070
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 11/14/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401640
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 11/14/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401642
Principal investigator 1 Janssen Research & Development, LLC $109.00 11/14/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175270080
Principal investigator 1 PFIZER INC. $1,432.60 11/14/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228716509
Recipient PFIZER INC. $940.00 11/14/2025 Covered Recipient Physician DISITAMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726868
Principal investigator 1 PFIZER INC. $1,556.08 11/13/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228730488
Principal investigator 1 PFIZER INC. $71,276.60 11/13/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228738044
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $500.00 11/12/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Vitros Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection No dispute reported 06/30/2026 1249804320
Principal investigator 1 Janssen Research & Development, LLC $7,483.00 11/10/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175354700
Principal investigator 1 PFIZER INC. $46,207.89 11/10/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228717249
Principal investigator 1 PFIZER INC. $46,207.89 11/10/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228718587
Principal investigator 1 Janssen Research & Development, LLC $1,768.00 11/07/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175269938
Principal investigator 1 Janssen Research & Development, LLC $7,979.00 11/07/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175355356
Principal investigator 1 Janssen Research & Development, LLC $27,520.00 11/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer No dispute reported 06/30/2026 1175355307
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $1,353.00 11/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Vitros Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection No dispute reported 06/30/2026 1249804294
Principal investigator 1 Sumitomo Pharma America, Inc. $1,036.00 11/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654637
Principal investigator 1 Sumitomo Pharma America, Inc. $900.00 11/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654807
Principal investigator 1 Sumitomo Pharma America, Inc. $1,036.00 11/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176654820
Recipient PFIZER INC. $940.00 11/04/2025 Covered Recipient Physician DISITAMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726802
Principal investigator 1 Daiichi Sankyo Inc. $51.75 11/03/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
DS1062-328 No dispute reported 06/30/2026 1223365347
Principal investigator 1 Daiichi Sankyo Inc. $94.00 11/03/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
DS1062-328 No dispute reported 06/30/2026 1223365349
Principal investigator 1 Daiichi Sankyo Inc. $376.00 11/03/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
DS1062-328 No dispute reported 06/30/2026 1223365351
Principal investigator 1 Janssen Research & Development, LLC $8,574.00 11/03/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175354652
Principal investigator 1 Janssen Research & Development, LLC $4,121.00 11/03/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175354834
Principal investigator 1 Janssen Research & Development, LLC $13,336.00 11/03/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175354907
Principal investigator 1 Janssen Research & Development, LLC $20,000.00 11/03/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1175354941
Principal investigator 1 Janssen Research & Development, LLC $5,320.00 11/03/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175355300
Recipient PFIZER INC. $330.00 11/03/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726822
Principal investigator 1 PFIZER INC. $221,237.47 11/01/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228737663
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,363.62 10/28/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combin No dispute reported 06/30/2026 1190313879
Recipient PFIZER INC. $620.00 10/24/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726748
Principal investigator 1 PFIZER INC. $789.10 10/24/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228741832
Principal investigator 1 Ferring Pharmaceuticals AS $762.30 10/23/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States No dispute reported 06/30/2026 1242061241
Principal investigator 1 Janssen Research & Development, LLC $36,722.00 10/23/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1175354602
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $71,098.00 10/22/2025 Non-covered Recipient Entity
Carolina Urologic Research Center Llc
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225409028
Recipient Novartis Pharmaceuticals Corporation $8,687.99 10/21/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291692
Recipient PFIZER INC. $330.00 10/21/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228720175
Recipient PFIZER INC. $330.00 10/21/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726798
Principal investigator 1 PFIZER INC. $24,627.30 10/21/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228741471
Principal investigator 1 Janssen Research & Development, LLC $6,078.00 10/20/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175355199
Principal investigator 1 Merck Sharp & Dohme LLC $7,050.00 10/20/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 No dispute reported 06/30/2026 1232927981
Recipient PFIZER INC. $940.00 10/18/2025 Covered Recipient Physician MEVROMETOSTAT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726750
Recipient PFIZER INC. $940.00 10/18/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726908
Recipient PFIZER INC. $940.00 10/18/2025 Covered Recipient Physician DISITAMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727177
Recipient PFIZER INC. $940.00 10/18/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727799
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 10/15/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401655
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 10/15/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401661
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,953.48 10/15/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409950
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,069.43 10/15/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410182
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,339.92 10/15/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410290
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $500.00 10/15/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Vitros Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection No dispute reported 06/30/2026 1249804257
Principal investigator 1 PFIZER INC. $546.00 10/14/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228740366
Principal investigator 1 PFIZER INC. $6,300.00 10/14/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH
A STUDY OF INTRAVESICAL ENFORTUMAB VEDOTIN FOR TREATMENT OF PATIENTS WITH NONMUSCLE INVASIVE BLADDER CANCER NMIBC No dispute reported 06/30/2026 1228741504
Principal investigator 1 PFIZER INC. $1,556.08 10/14/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228741954
Principal investigator 1 Janssen Research & Development, LLC $1,378.50 10/13/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175354842
Principal investigator 1 Janssen Research & Development, LLC $2,107.00 10/10/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175354693
Principal investigator 1 Ferring Pharmaceuticals AS $12,800.00 10/09/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer No dispute reported 06/30/2026 1242061116
Principal investigator 1 PFIZER INC. $58,339.10 10/09/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228740783
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $13,530.00 10/08/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Vitros Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection No dispute reported 06/30/2026 1249804252
Principal investigator 1 PFIZER INC. $13,325.67 10/07/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228730682
Principal investigator 1 Janssen Research & Development, LLC $6,163.00 10/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175354679
Principal investigator 1 Janssen Research & Development, LLC $5,402.00 10/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175354758
Principal investigator 1 Janssen Research & Development, LLC $7,105.00 10/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175354784
Principal investigator 1 Janssen Research & Development, LLC $4,260.00 10/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175354885
Principal investigator 1 Janssen Research & Development, LLC $1,351.00 10/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175354997
Principal investigator 1 Janssen Research & Development, LLC $431.00 10/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175355174
Principal investigator 1 Janssen Research & Development, LLC $1,912.00 10/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175355206
Principal investigator 1 Janssen Research & Development, LLC $4,225.00 10/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175355232
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 10/03/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401653
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 10/03/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401657
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 10/03/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401659
Principal investigator 1 Janssen Research & Development, LLC $3,446.00 10/03/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175355077
Principal investigator 1 Janssen Research & Development, LLC $32,987.00 10/02/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER L
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175354817
Principal investigator 1 Laborie Medical Technologies Corp. $3,375.00 10/02/2025 Non-covered Recipient Entity
CURC Carolina Urologic Research Ctr LLC
PINNACLE No dispute reported 06/30/2026 1250724522
Principal investigator 1 Laborie Medical Technologies Corp. $1,655.00 10/02/2025 Non-covered Recipient Entity
CURC Carolina Urologic Research Ctr LLC
PINNACLE No dispute reported 06/30/2026 1250724524
Principal investigator 1 MEDIVATION LLC. $1,287.00 10/02/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228747739
Principal investigator 1 Celgene Corporation $17,800.00 09/30/2025 Non-covered Recipient Entity
Carolina Urologic Research Center, Llc
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge No dispute reported 06/30/2026 1222305622
Principal investigator 1 PFIZER INC. $46,207.89 09/30/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228717247
Principal investigator 1 PFIZER INC. $46,207.89 09/30/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228718471
Principal investigator 1 PFIZER INC. $46,207.89 09/30/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228723754
Principal investigator 1 PFIZER INC. $46,207.89 09/29/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228727167
Principal investigator 1 Novartis Pharmaceuticals Corporation $42,585.58 09/26/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190297730
Recipient PFIZER INC. $940.00 09/25/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727221
Principal investigator 1 PFIZER INC. $2,080.00 09/24/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228757750
Principal investigator 1 Astellas Pharma Global Development $1,200.00 09/23/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234182436
Principal investigator 1 Astellas Pharma Global Development $500.00 09/23/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234182440
Principal investigator 1 Astellas Pharma Global Development $300.00 09/23/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234182444
Principal investigator 1 Novartis Pharmaceuticals Corporation $76,338.66 09/22/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) No dispute reported 06/30/2026 1190299791
Principal investigator 1 PFIZER INC. $30,805.26 09/22/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228716593
Principal investigator 1 MEDIVATION LLC. $5,995.60 09/18/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228742553
Principal investigator 1 Organon Llc $788.61 09/17/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
3475-676 No dispute reported 06/30/2026 1173042396
Principal investigator 1 Exelixis Inc. $5,376.00 09/16/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222380312
Principal investigator 1 Janssen Research & Development, LLC $5,619.00 09/15/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175355113
Principal investigator 1 Janssen Research & Development, LLC $4,884.00 09/15/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175355214
Principal investigator 1 Novartis Pharmaceuticals Corporation $24,826.82 09/15/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of Lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and Lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway In No dispute reported 06/30/2026 1190299783
Principal investigator 1 PFIZER INC. $1,746.36 09/13/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228757446
Principal investigator 1 Astellas Pharma Global Development $1,242.00 09/12/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234182438
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,971.70 09/12/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) No dispute reported 06/30/2026 1185542074
Principal investigator 1 Ferring Pharmaceuticals AS $228.36 09/11/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States No dispute reported 06/30/2026 1242061003
Principal investigator 1 Blue Earth Diagnostics $10,000.00 09/10/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy No dispute reported 06/30/2026 1253758585
Principal investigator 1 PFIZER INC. $31,655.00 09/09/2025 Non-covered Recipient Entity
START San Antonio LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 No dispute reported 06/30/2026 1228754406
Principal investigator 1 Janssen Research & Development, LLC $18,009.00 09/08/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175354824
Principal investigator 1 Janssen Research & Development, LLC $4,851.00 09/08/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175355004
Principal investigator 1 Janssen Research & Development, LLC $1,768.00 09/05/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175270048
Principal investigator 1 Astellas Pharma Global Development $489.00 09/04/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234182442
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $21,060.00 09/04/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410828
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $780.00 09/04/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411048
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,500.00 09/04/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411166
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $14,976.00 09/04/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411472
Principal investigator 1 Janssen Research & Development, LLC $3,184.00 09/04/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175355120
Principal investigator 1 Exelixis Inc. $359.55 09/01/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222380314
Principal investigator 1 Janssen Research & Development, LLC $459.00 09/01/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175354687
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 08/28/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401608
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 08/28/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401610
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 08/28/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401616
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 08/28/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401618
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 08/28/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401622
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 08/28/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401624
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 08/28/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401626
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 08/28/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401628
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,733.68 08/28/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409394
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,953.48 08/28/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409460
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,451.29 08/28/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409480
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $6,874.57 08/28/2025 Non-covered Recipient Entity
Inova Health Care Services
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409514
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,733.68 08/28/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225409528
Principal investigator 1 Novartis Pharmaceuticals Corporation $32,647.88 08/27/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190299787
Recipient PFIZER INC. $3,200.00 08/27/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726556
Principal investigator 1 Novartis Pharmaceuticals Corporation $49,004.10 08/26/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer No dispute reported 06/30/2026 1190306637
Principal investigator 1 Janssen Research & Development, LLC $459.50 08/25/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175354809
Principal investigator 1 PFIZER INC. $35,508.00 08/22/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228787444
Principal investigator 1 PFIZER INC. $856.26 08/22/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228787734
Principal investigator 1 Ferring Pharmaceuticals AS $1,524.60 08/21/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States No dispute reported 06/30/2026 1242060869
Recipient PFIZER INC. $3,200.00 08/21/2025 Covered Recipient Physician PF06821497 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726316
Principal investigator 1 Janssen Research & Development, LLC $4,726.00 08/18/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175354794
Principal investigator 1 Janssen Research & Development, LLC $2,112.00 08/18/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175355136
Principal investigator 1 Janssen Research & Development, LLC $5,716.00 08/18/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175355147
Principal investigator 1 Janssen Research & Development, LLC $8,404.00 08/18/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175355165
Principal investigator 1 Janssen Research & Development, LLC $173.00 08/18/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175355284
Principal investigator 1 PFIZER INC. $46,207.89 08/18/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228717479
Principal investigator 1 PFIZER INC. $46,207.89 08/18/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228718592
Principal investigator 1 Janssen Research & Development, LLC $9,277.00 08/15/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer No dispute reported 06/30/2026 1175354900
Principal investigator 1 Janssen Research & Development, LLC $40,882.00 08/15/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer No dispute reported 06/30/2026 1175355025
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,629.19 08/15/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190306605
Principal investigator 1 PFIZER INC. $1,556.08 08/13/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228786042
Principal investigator 1 Janssen Research & Development, LLC $5,009.00 08/11/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175354765
Principal investigator 1 Janssen Research & Development, LLC $17,191.00 08/11/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175355240
Recipient PFIZER INC. $330.00 08/11/2025 Covered Recipient Physician DISITAMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726800
Principal investigator 1 PFIZER INC. $3,112.16 08/09/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228766751
Recipient Novartis Pharmaceuticals Corporation $1,431.62 08/05/2025 Covered Recipient Physician HEOR No dispute reported 06/30/2026 1190292049
Recipient PFIZER INC. $330.00 08/05/2025 Covered Recipient Physician DISITAMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727431
Principal investigator 1 Janssen Research & Development, LLC $3,654.00 08/04/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175354742
Principal investigator 1 Janssen Research & Development, LLC $630.00 08/04/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175354778
Principal investigator 1 Janssen Research & Development, LLC $1,310.00 08/04/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175354801
Principal investigator 1 Janssen Research & Development, LLC $862.00 08/04/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175354851
Principal investigator 1 Janssen Research & Development, LLC $16,878.00 08/04/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175355347
Recipient PFIZER INC. $330.00 08/01/2025 Covered Recipient Physician DISITAMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726888
Principal investigator 1 Sumitomo Pharma America, Inc. $1,036.00 08/01/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641782
Principal investigator 1 Sumitomo Pharma America, Inc. $2,132.00 08/01/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176641831
Principal investigator 1 Janssen Research & Development, LLC $5,866.00 07/28/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175354981
Principal investigator 1 Janssen Research & Development, LLC $19,298.00 07/28/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175355271
Principal investigator 1 PFIZER INC. $30,805.26 07/28/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228716591
Principal investigator 1 Janssen Research & Development, LLC $8,603.00 07/25/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175355034
Principal investigator 1 Janssen Research & Development, LLC $4,299.00 07/25/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175355315
Principal investigator 1 PFIZER INC. $5,090.80 07/25/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228787411
Principal investigator 1 Janssen Research & Development, LLC $39,619.00 07/23/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175270073
Principal investigator 1 Janssen Research & Development, LLC $654.00 07/23/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175270182
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $70,317.00 07/21/2025 Non-covered Recipient Entity
Carolina Urologic Research Center Llc
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402421
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $252.00 07/18/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408658
Principal investigator 1 Janssen Research & Development, LLC $15,300.00 07/17/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer No dispute reported 06/30/2026 1175355278
Principal investigator 1 Exelixis Inc. $12,744.90 07/16/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222380310
Principal investigator 1 PFIZER INC. $2,180.10 07/16/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228762357
Principal investigator 1 Janssen Research & Development, LLC $1,768.00 07/14/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175270207
Recipient PFIZER INC. $330.00 07/11/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727219
Principal investigator 1 Janssen Research & Development, LLC $2,626.00 07/07/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175354644
Principal investigator 1 Janssen Research & Development, LLC $28,341.00 07/07/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175354973
Principal investigator 1 Janssen Research & Development, LLC $1,885.00 07/07/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175355092
Principal investigator 1 Janssen Research & Development, LLC $1,452.00 07/07/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175355193
Principal investigator 1 Janssen Research & Development, LLC $8,982.00 07/07/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175355294
Principal investigator 1 Janssen Research & Development, LLC $11,031.00 07/04/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175355049
Principal investigator 1 Janssen Research & Development, LLC $7,366.00 07/04/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175355098
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $15,900.00 07/03/2025 Non-covered Recipient Entity
Carolina Urologic Research Center Llc
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402369
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $5,356.00 07/03/2025 Non-covered Recipient Entity
Carolina Urologic Research Center Llc
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402423
Principal investigator 1 MEDIVATION LLC. $286.00 07/03/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228743064
Principal investigator 1 MEDIVATION LLC. $1,287.00 07/03/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228755528
Principal investigator 1 PFIZER INC. $46,207.89 07/02/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726472
Principal investigator 1 PFIZER INC. $46,207.89 07/01/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228726390
Principal investigator 1 Janssen Research & Development, LLC $3,836.00 06/30/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175355128
Principal investigator 1 PFIZER INC. $789.10 06/27/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228776081
Principal investigator 1 PFIZER INC. $2,180.10 06/25/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228786751
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 06/24/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
ProvONE No dispute reported 06/30/2026 1247892234
Principal investigator 1 PFIZER INC. $800.00 06/24/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228761103
Principal investigator 1 Janssen Research & Development, LLC $4,000.00 06/23/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175270147
Principal investigator 1 Janssen Research & Development, LLC $12,182.00 06/23/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175355018
Principal investigator 1 Janssen Research & Development, LLC $3,899.00 06/20/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175270037
Principal investigator 1 Janssen Research & Development, LLC $525.00 06/20/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175270128
Principal investigator 1 Laborie Medical Technologies Corp. $562.50 06/19/2025 Non-covered Recipient Entity
CURC Carolina Urologic Research Ctr LLC
PINNACLE No dispute reported 06/30/2026 1250724526
Principal investigator 1 Janssen Research & Development, LLC $1,841.00 06/16/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175270011
Principal investigator 1 Janssen Research & Development, LLC $1,446.00 06/16/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175355083
Recipient PFIZER INC. $940.00 06/14/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228771218
Principal investigator 1 Exelixis Inc. $10,752.00 06/11/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222380308
Principal investigator 1 PFIZER INC. $2,080.00 06/07/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228775504
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $94,520.00 06/06/2025 Non-covered Recipient Entity
Carolina Urologic Research Center Llc
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402373
Principal investigator 1 Janssen Research & Development, LLC $20,312.00 06/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175354933
Principal investigator 1 Astellas Pharma Global Development $489.00 06/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234182434
Principal investigator 1 Dendreon Pharmaceuticals LLC $50.00 06/05/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
ProvONE No dispute reported 06/30/2026 1247892102
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 06/05/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
ProvONE No dispute reported 06/30/2026 1247892106
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,550.00 06/05/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
ProvONE No dispute reported 06/30/2026 1247892112
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,600.00 06/05/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
ProvONE No dispute reported 06/30/2026 1247892119
Principal investigator 1 Dendreon Pharmaceuticals LLC $150.00 06/05/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
ProvONE No dispute reported 06/30/2026 1247892123
Principal investigator 1 Dendreon Pharmaceuticals LLC $800.00 06/05/2025 Non-covered Recipient Entity
LANCASTER UROLOGY PC DBA KEYSTONE
ProvONE No dispute reported 06/30/2026 1247892126
Principal investigator 1 MEDIVATION LLC. $286.00 06/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228722462
Principal investigator 1 MEDIVATION LLC. $286.00 06/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228723272
Principal investigator 1 MEDIVATION LLC. $286.00 06/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228779733
Principal investigator 1 MEDIVATION LLC. $286.00 06/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228780850
Principal investigator 1 MEDIVATION LLC. $286.00 06/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791023
Principal investigator 1 MEDIVATION LLC. $286.00 06/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791316
Principal investigator 1 MEDIVATION LLC. $286.00 06/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791610
Principal investigator 1 MEDIVATION LLC. $286.00 06/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792278
Principal investigator 1 MEDIVATION LLC. $286.00 06/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792282
Principal investigator 1 MEDIVATION LLC. $286.00 06/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228793719
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 06/04/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401572
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 06/04/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401574
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 06/04/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401576
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 06/04/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401578
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 06/04/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401580
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 06/04/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401584
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 06/04/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401586
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 06/04/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401588
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 06/04/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401592
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 06/04/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401594
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,953.48 06/04/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research Llc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407998
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,733.68 06/04/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408034
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,733.68 06/04/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408136
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $325.83 06/04/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research Llc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408174
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,339.92 06/04/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408228
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,451.29 06/04/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408310
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,733.68 06/04/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408358
Principal investigator 1 Merck Sharp & Dohme LLC $2,700.00 06/04/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
STUDY NAME# A Non-Interventional Retrospective Real-World Study to Assess Treatment Patterns, Surrogate Endpoints and Overall Survival in Muscle Invasive Bladder Cancer No dispute reported 06/30/2026 1232935887
Principal investigator 1 Merck Sharp & Dohme LLC $997.32 06/04/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK 7684A Vibostolimab with Pembrolizumab Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma KEYVIBE-010 No dispute reported 06/30/2026 1232936486
Principal investigator 1 Janssen Research & Development, LLC $890.00 06/02/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175355053
Principal investigator 1 Janssen Research & Development, LLC $18,592.00 06/02/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-m No dispute reported 06/30/2026 1175355376
Recipient PFIZER INC. $940.00 06/01/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769180
Recipient PFIZER INC. $940.00 05/31/2025 Covered Recipient Physician SASANLIMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228751815
Recipient PFIZER INC. $940.00 05/31/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228751966
Recipient PFIZER INC. $940.00 05/31/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228753341
Recipient PFIZER INC. $940.00 05/31/2025 Covered Recipient Physician SASANLIMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228771236
Principal investigator 1 Janssen Research & Development, LLC $2,138.00 05/29/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175355220
Principal investigator 1 PFIZER INC. $1,746.36 05/29/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228772268
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $436.80 05/28/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407408
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $436.80 05/28/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407410
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,001.19 05/28/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407610
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $436.80 05/28/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407622
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $329.55 05/28/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225407624
Recipient Novartis Pharma AG $1,204.70 05/23/2025 Covered Recipient Physician CAAA617B12302 No dispute reported 06/30/2026 1248109481
Principal investigator 1 Laborie Medical Technologies Corp. $1,092.50 05/22/2025 Non-covered Recipient Entity
CURC Carolina Urologic Research Ctr LLC
PINNACLE No dispute reported 06/30/2026 1250724528
Principal investigator 1 PFIZER INC. $4,360.20 05/22/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228773471
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $375.00 05/21/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401552
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $282.82 05/21/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401568
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $282.82 05/21/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225401570
Principal investigator 1 Janssen Research & Development, LLC $375.00 05/19/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175269985
Principal investigator 1 Janssen Research & Development, LLC $5,204.00 05/19/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175269995
Principal investigator 1 Janssen Research & Development, LLC $273.00 05/19/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175270120
Principal investigator 1 Janssen Research & Development, LLC $1,581.00 05/19/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175270155
Principal investigator 1 Janssen Research & Development, LLC $527.00 05/19/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175270189
Principal investigator 1 Janssen Research & Development, LLC $7,452.00 05/19/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175354628
Principal investigator 1 Janssen Research & Development, LLC $2,597.00 05/16/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175269946
Principal investigator 1 Janssen Research & Development, LLC $1,014.00 05/16/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175270001
Principal investigator 1 Ferring Pharmaceuticals AS $4,839.12 05/15/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States No dispute reported 06/30/2026 1242060349
Principal investigator 1 Janssen Research & Development, LLC $5,682.00 05/15/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175269977
Principal investigator 1 Janssen Research & Development, LLC $1,784.00 05/15/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175270026
Principal investigator 1 Janssen Research & Development, LLC $9,875.00 05/15/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175270064
Principal investigator 1 Janssen Research & Development, LLC $19,946.00 05/15/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175270086
Principal investigator 1 Janssen Research & Development, LLC $14,205.00 05/15/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175270225
Principal investigator 1 Janssen Research & Development, LLC $16,401.00 05/14/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175270114
Principal investigator 1 PFIZER INC. $1,432.60 05/14/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228763489
Recipient PFIZER INC. $330.00 05/13/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228751376
Recipient PFIZER INC. $330.00 05/13/2025 Covered Recipient Physician PF06821497 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228752116
Recipient PFIZER INC. $330.00 05/13/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228753673
Recipient PFIZER INC. $330.00 05/13/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760831
Recipient PFIZER INC. $330.00 05/13/2025 Covered Recipient Physician SASANLIMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228768665
Principal investigator 1 Janssen Research & Development, LLC $300.00 05/12/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175269922
Principal investigator 1 Janssen Research & Development, LLC $2,598.00 05/12/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175269954
Principal investigator 1 Janssen Research & Development, LLC $1,014.00 05/12/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175270166
Principal investigator 1 Janssen Research & Development, LLC $1,770.00 05/12/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175270174
Principal investigator 1 Janssen Research & Development, LLC $2,652.00 05/12/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175270197
Principal investigator 1 Janssen Research & Development, LLC $6,215.00 05/12/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175354965
Principal investigator 1 MEDIVATION LLC. $1,462.50 05/08/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791495
Principal investigator 1 MEDIVATION LLC. $286.00 05/08/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228791975
Principal investigator 1 MEDIVATION LLC. $1,287.00 05/08/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228792230
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 05/07/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634094
Principal investigator 1 Sumitomo Pharma America, Inc. $30.00 05/07/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634113
Principal investigator 1 Janssen Research & Development, LLC $862.00 05/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175354926
Principal investigator 1 Janssen Research & Development, LLC $33,040.00 05/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175355225
Principal investigator 1 PFIZER INC. $46,207.89 05/05/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228768714
Principal investigator 1 PFIZER INC. $4,033.74 05/03/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228773284
Recipient PFIZER INC. $330.00 05/01/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228768259
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,293.46 04/30/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 1185542077
Principal investigator 1 PFIZER INC. $46,207.89 04/29/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228755064
Principal investigator 1 PFIZER INC. $46,207.89 04/29/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228757024
Principal investigator 1 Janssen Research & Development, LLC $3,301.00 04/28/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175269908
Principal investigator 1 Janssen Research & Development, LLC $48,738.00 04/28/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175355324
Principal investigator 1 Merck Sharp & Dohme LLC $74,099.70 04/28/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer No dispute reported 06/30/2026 1232927579
Recipient Novartis Pharma AG $615.80 04/28/2025 Covered Recipient Physician CAAA617D12302 No dispute reported 06/30/2026 1248109479
Recipient PFIZER INC. $940.00 04/27/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769429
Recipient PFIZER INC. $940.00 04/26/2025 Covered Recipient Physician SASANLIMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228751683
Principal investigator 1 Janssen Research & Development, LLC $6,954.00 04/25/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175355371
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 04/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401458
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 04/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401472
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $4,500.00 04/23/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Vitros Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection No dispute reported 06/30/2026 1249803901
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $39,237.00 04/23/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Vitros Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection No dispute reported 06/30/2026 1249803905
Recipient PFIZER INC. $330.00 04/18/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228759596
Principal investigator 1 Laborie Medical Technologies Corp. $1,655.00 04/17/2025 Non-covered Recipient Entity
CURC Carolina Urologic Research Ctr LLC
PINNACLE No dispute reported 06/30/2026 1250724530
Principal investigator 1 PFIZER INC. $8,591.70 04/16/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228781458
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $252.00 04/14/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404299
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,260.00 04/14/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405312
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,260.00 04/14/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406188
Principal investigator 1 PFIZER INC. $46,206.12 04/14/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228752369
Principal investigator 1 PFIZER INC. $46,206.12 04/12/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228751333
Principal investigator 1 PFIZER INC. $46,207.89 04/12/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754339
Principal investigator 1 Exelixis Inc. $29,475.35 04/11/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222380306
Principal investigator 1 Janssen Research & Development, LLC $1,533.00 04/10/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175270135
Principal investigator 1 Merck Sharp & Dohme LLC $6,375.00 04/09/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 1232926915
Principal investigator 1 Sumitomo Pharma America, Inc. $507.00 04/09/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176632842
Principal investigator 1 Sumitomo Pharma America, Inc. $2,072.00 04/09/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632987
Principal investigator 1 Sumitomo Pharma America, Inc. $1,126.00 04/09/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176633008
Principal investigator 1 PFIZER INC. $2,869.10 04/08/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228778977
Principal investigator 1 Janssen Research & Development, LLC $35,577.00 04/07/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175354662
Recipient PFIZER INC. $1,400.00 04/04/2025 Covered Recipient Physician SASANLIMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228752885
Principal investigator 1 MEDIVATION LLC. $286.00 04/03/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228789849
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $41,907.00 04/02/2025 Non-covered Recipient Entity
Carolina Urologic Research Center Llc
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402377
Principal investigator 1 Janssen Research & Development, LLC $2,907.00 03/31/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175355263
Principal investigator 1 Exelixis Inc. $4,225.00 03/28/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222380298
Recipient PFIZER INC. $3,200.00 03/27/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228768860
Principal investigator 1 Exelixis Inc. $151,553.70 03/26/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222380302
Principal investigator 1 Exelixis Inc. $22,146.70 03/26/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222380304
Principal investigator 1 Laborie Medical Technologies Corp. $1,655.00 03/26/2025 Non-covered Recipient Entity
CURC Carolina Urologic Research Ctr LLC
PINNACLE No dispute reported 06/30/2026 1250724532
Principal investigator 1 Merck Sharp & Dohme LLC $566.56 03/26/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926569
Principal investigator 1 PFIZER INC. $61,610.52 03/25/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228760491
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 03/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401448
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 03/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401474
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 03/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401490
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 03/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401494
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 03/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401520
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 03/24/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401546
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,733.68 03/24/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404207
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,733.68 03/24/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405314
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,733.68 03/24/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406190
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,733.68 03/24/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225407186
Principal investigator 1 Exelixis Inc. $650.00 03/24/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222380320
Principal investigator 1 Exelixis Inc. $16,890.00 03/24/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222380326
Principal investigator 1 Janssen Research & Development, LLC $17,149.00 03/24/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175355158
Principal investigator 1 PFIZER INC. $72,126.30 03/22/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228794468
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $74,631.00 03/21/2025 Non-covered Recipient Entity
Carolina Urologic Research Center Llc
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402371
Principal investigator 1 PFIZER INC. $5,088.32 03/21/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228783105
Principal investigator 1 PFIZER INC. $8,720.40 03/21/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL No dispute reported 06/30/2026 1228797519
Principal investigator 1 Astellas Pharma Global Development $1,242.00 03/19/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234182432
Principal investigator 1 Exelixis Inc. $1,500.00 03/17/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222380322
Principal investigator 1 Exelixis Inc. $2,000.00 03/17/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222380330
Principal investigator 1 Janssen Research & Development, LLC $9,442.00 03/17/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175354769
Principal investigator 1 Merck Sharp & Dohme LLC $350.00 03/12/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
STUDY NAME# A Non-Interventional Retrospective Real-World Study to Assess Treatment Patterns, Surrogate Endpoints and Overall Survival in Muscle Invasive Bladder Cancer No dispute reported 06/30/2026 1232935929
Principal investigator 1 Janssen Research & Development, LLC $29,145.00 03/10/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175355042
Principal investigator 1 PFIZER INC. $30,805.26 03/10/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228760455
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228724340
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774140
Principal investigator 1 MEDIVATION LLC. $1,287.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774475
Principal investigator 1 MEDIVATION LLC. $16,686.80 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774935
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775032
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775091
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775571
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228775581
Principal investigator 1 MEDIVATION LLC. $1,287.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776467
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228776665
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777002
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777130
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777328
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777757
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777782
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228778214
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228785600
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228785908
Principal investigator 1 MEDIVATION LLC. $286.00 03/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228786937
Principal investigator 1 Janssen Research & Development, LLC $11,604.00 03/05/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175269929
Principal investigator 1 Sumitomo Pharma America, Inc. $2,275.00 03/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630200
Principal investigator 1 Sumitomo Pharma America, Inc. $63.00 03/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630204
Principal investigator 1 Sumitomo Pharma America, Inc. $1,781.70 03/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630208
Principal investigator 1 Sumitomo Pharma America, Inc. $500.00 03/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630212
Principal investigator 1 Sumitomo Pharma America, Inc. $4,000.00 03/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630217
Principal investigator 1 Sumitomo Pharma America, Inc. $1,734.27 03/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630222
Principal investigator 1 Sumitomo Pharma America, Inc. $100.00 03/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630227
Principal investigator 1 Sumitomo Pharma America, Inc. $100.00 03/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630232
Principal investigator 1 Janssen Research & Development, LLC $890.00 03/03/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175354620
Principal investigator 1 Janssen Research & Development, LLC $31,626.00 03/03/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175354989
Principal investigator 1 PFIZER INC. $92,415.78 02/27/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228754906
Principal investigator 1 PFIZER INC. $92,415.78 02/27/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228756533
Recipient PFIZER INC. $3,200.00 02/27/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760745
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 02/26/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401456
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 02/26/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401496
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 02/26/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401542
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,500.00 02/26/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404209
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $780.00 02/26/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404301
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $14,976.00 02/26/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225404303
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $21,060.00 02/26/2025 Non-covered Recipient Entity
Charleston Neuroscience Institute
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405316
Principal investigator 1 Merck Sharp & Dohme LLC $1,281.60 02/26/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
Phase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-365 No dispute reported 06/30/2026 1232925769
Principal investigator 1 PFIZER INC. $1,008.24 02/24/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228761205
Principal investigator 1 PFIZER INC. $3,658.20 02/22/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228770740
Principal investigator 1 Janssen Research & Development, LLC $150,192.00 02/21/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175269916
Principal investigator 1 Janssen Research & Development, LLC $20,670.00 02/20/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175269963
Principal investigator 1 Janssen Research & Development, LLC $7,995.00 02/20/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175270056
Principal investigator 1 Janssen Research & Development, LLC $82,850.00 02/20/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175270216
Principal investigator 1 Janssen Research & Development, LLC $2,169.00 02/17/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175354707
Recipient PFIZER INC. $3,200.00 02/15/2025 Covered Recipient Physician SASANLIMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228771109
Principal investigator 1 Exelixis Inc. $5,401.00 02/14/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222380324
Principal investigator 1 Exelixis Inc. $4,067.12 02/14/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222380328
Principal investigator 1 Exelixis Inc. $1,600.00 02/14/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222380332
Principal investigator 1 Janssen Research & Development, LLC $2,122.00 02/14/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175269970
Recipient PFIZER INC. $330.00 02/14/2025 Covered Recipient Physician SASANLIMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760688
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $25,202.07 02/13/2025 Non-covered Recipient Entity
Carolina Urologic Research Center Llc
BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical No dispute reported 06/30/2026 1225402375
Principal investigator 1 Genentech, Inc. $4,555.00 02/13/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Phase III Ipatasertib plus abiraterone in mCRPC 1st Line No dispute reported 06/30/2026 1211583996
Principal investigator 1 Janssen Research & Development, LLC $5,558.00 02/13/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175270097
Recipient PFIZER INC. $940.00 02/13/2025 Covered Recipient Physician PF06821497 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228751990
Recipient PFIZER INC. $940.00 02/13/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228759802
Recipient PFIZER INC. $940.00 02/13/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760484
Principal investigator 1 Exelixis Inc. $13,064.00 02/10/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222380300
Principal investigator 1 Janssen Research & Development, LLC $31,086.00 02/10/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175354725
Principal investigator 1 Eli Lilly and Company $8,401.03 02/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) No dispute reported 06/30/2026 1187878585
Principal investigator 1 PFIZER INC. $1,008.24 02/06/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228760077
Principal investigator 1 PFIZER INC. $46,207.89 02/06/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 No dispute reported 06/30/2026 1228768881
Principal investigator 1 Exelixis Inc. $846.00 02/05/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222380334
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 02/03/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401498
Principal investigator 1 Janssen Research & Development, LLC $1,828.50 02/03/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy No dispute reported 06/30/2026 1175354717
Principal investigator 1 Janssen Research & Development, LLC $1,752.00 02/03/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175354874
Principal investigator 1 Merck Sharp & Dohme LLC $33,210.24 02/03/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
Phase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-365 No dispute reported 06/30/2026 1232925939
Recipient PFIZER INC. $940.00 02/03/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228751656
Recipient PFIZER INC. $940.00 02/03/2025 Covered Recipient Physician ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770631
Principal investigator 1 AstraZeneca UK Limited $762,065.50 01/31/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA) No dispute reported 06/30/2026 1185542072
Recipient Novartis Pharma AG $509.29 01/30/2025 Covered Recipient Physician CAAA617D12302 No dispute reported 06/30/2026 1248109477
Principal investigator 1 AstraZeneca Pharmaceuticals LP $245,681.01 01/29/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco No dispute reported 06/30/2026 1185542080
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,233.05 01/29/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401446
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 01/29/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401454
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,233.05 01/29/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401468
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,233.05 01/29/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401482
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 01/29/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401484
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,233.05 01/29/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401486
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,233.05 01/29/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401492
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,233.05 01/29/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401514
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 01/29/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401516
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,233.05 01/29/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401518
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,233.05 01/29/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401526
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 01/29/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401528
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician PF06821497 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760631
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228760721
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician SASANLIMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228768984
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769246
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician TALAZOPARIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769843
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician SASANLIMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228769917
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician PF06821497 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770404
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician PF06821497 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770589
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,943.33 01/27/2025 Covered Recipient Teaching Hospital
Karmanos Cancer Hospital
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225401470
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,953.48 01/27/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research Llc
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225403357
Principal investigator 1 Janssen Research & Development, LLC $7,173.00 01/27/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175354892
Principal investigator 1 PFIZER INC. $2,080.00 01/25/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228801327
Principal investigator 1 Janssen Research & Development, LLC $20,000.00 01/24/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc No dispute reported 06/30/2026 1175355071
Principal investigator 1 Novartis Pharmaceuticals Corporation $154,783.81 01/22/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer No dispute reported 06/30/2026 1190306639
Principal investigator 1 PFIZER INC. $92,415.78 01/21/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228754910
Principal investigator 1 PFIZER INC. $92,415.78 01/21/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228757373
Principal investigator 1 Eli Lilly and Company $3,000.00 01/16/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
AN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS No dispute reported 06/30/2026 1187878695
Principal investigator 1 Novartis Pharmaceuticals Corporation $257.88 01/15/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of Lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and Lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway In No dispute reported 06/30/2026 1190306601
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,682.10 01/15/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190306603
Principal investigator 1 Novartis Pharmaceuticals Corporation $46,678.46 01/15/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) No dispute reported 06/30/2026 1190306635
Principal investigator 1 PFIZER INC. $7,959.90 01/15/2025 Non-covered Recipient Entity
Carolina Urologic Research Center LLC
TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER No dispute reported 06/30/2026 1228798305
Principal investigator 1 Janssen Research & Development, LLC $7,599.00 01/14/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175270103
Principal investigator 1 Janssen Research & Development, LLC $2,122.00 01/13/2025 Non-covered Recipient Entity
Carolina Urologic Rsrch Ctr
A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder No dispute reported 06/30/2026 1175270020
Recipient Novartis Pharmaceuticals Corporation $7,425.55 01/13/2025 Covered Recipient Physician HEOR No dispute reported 06/30/2026 1190292054
Principal investigator 1 PFIZER INC. $46,206.12 01/13/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754177
Principal investigator 1 PFIZER INC. $46,206.12 01/12/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228754180
Principal investigator 1 PFIZER INC. $46,207.89 01/12/2025 Non-covered Recipient Entity
Carolina Urologic Research Center
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228756242
Principal investigator 1 AstraZeneca Pharmaceuticals LP $688,758.90 01/08/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER, LLC
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185542082
Principal investigator 1 Astellas Pharma Global Development $978.00 01/07/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234182430
Principal investigator 1 Janssen Research & Development, LLC $8,040.00 01/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175354869
Principal investigator 1 Janssen Research & Development, LLC $9,587.00 01/06/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions No dispute reported 06/30/2026 1175355253
Principal investigator 1 Janssen Research & Development, LLC $129,696.00 01/02/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175354733
Principal investigator 1 MEDIVATION LLC. $1,287.00 01/02/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228774967
Principal investigator 1 MEDIVATION LLC. $1,125.50 01/02/2025 Non-covered Recipient Entity
CAROLINA UROLOGIC RESEARCH CENTER LLC
A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY No dispute reported 06/30/2026 1228777483

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 2
PY2024 Value of interest $4,471,851.45 2
PY2023 Amount invested $0.00 1
PY2023 Value of interest $1,458,965.61 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $704,328.23 1
PY2021 Amount invested $503,091.59 1
PY2021 Value of interest $654,019.10 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

5 records · PY2021–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 SN Holdings, LLC $0.00 $17,278.77 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124771677
PY2024 SN Holdings, LLC $0.00 $4,454,572.68 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124773425
PY2023 SN Holdings, LLC $0.00 $1,458,965.61 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1032887523
PY2022 SN Holdings, LLC $0.00 $704,328.23 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 941609497
PY2021 SN Holdings, LLC $503,091.59 $654,019.10 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 820125429